Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Identifieur interne : 003822 ( Main/Exploration ); précédent : 003821; suivant : 003823Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Auteurs : Simona Soverini [Italie] ; Susan Branford [Australie] ; Franck E. Nicolini [France] ; Moshe Talpaz [États-Unis] ; Michael W N. Deininger [États-Unis] ; Giovanni Martinelli [Italie] ; Martin C. Müller [Allemagne] ; Jerald P. Radich [États-Unis] ; Neil P. Shah [États-Unis]Source :
- Leukemia research [ 1873-5835 ] ; 2014.
Descripteurs français
- KwdFr :
- Analyse de mutations d'ADN (), Analyse de mutations d'ADN (tendances), Guides de bonnes pratiques cliniques comme sujet, Humains, Inhibiteurs de protéines kinases (pharmacologie), Inhibiteurs de protéines kinases (usage thérapeutique), Leucémie myéloïde chronique BCR-ABL positive (génétique), Leucémie myéloïde chronique BCR-ABL positive (traitement médicamenteux), Mutation, Pronostic, Protéines de fusion bcr-abl (génétique), Prévision, Résistance aux médicaments antinéoplasiques (génétique).
- MESH :
- génétique : Leucémie myéloïde chronique BCR-ABL positive, Protéines de fusion bcr-abl, Résistance aux médicaments antinéoplasiques.
- pharmacologie : Inhibiteurs de protéines kinases.
- tendances : Analyse de mutations d'ADN.
- traitement médicamenteux : Leucémie myéloïde chronique BCR-ABL positive.
- usage thérapeutique : Inhibiteurs de protéines kinases.
- Analyse de mutations d'ADN, Guides de bonnes pratiques cliniques comme sujet, Humains, Mutation, Pronostic, Prévision.
English descriptors
- KwdEn :
- DNA Mutational Analysis (methods), DNA Mutational Analysis (trends), Drug Resistance, Neoplasm (genetics), Forecasting, Fusion Proteins, bcr-abl (genetics), Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics), Mutation, Practice Guidelines as Topic, Prognosis, Protein Kinase Inhibitors (pharmacology), Protein Kinase Inhibitors (therapeutic use).
- MESH :
- chemical , genetics : Fusion Proteins, bcr-abl.
- drug therapy : Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- genetics : Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- methods : DNA Mutational Analysis.
- chemical , pharmacology : Protein Kinase Inhibitors.
- chemical , therapeutic use : Protein Kinase Inhibitors.
- trends : DNA Mutational Analysis.
- Forecasting, Humans, Mutation, Practice Guidelines as Topic, Prognosis.
Abstract
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.
DOI: 10.1016/j.leukres.2013.09.011
PubMed: 24131888
Affiliations:
- Allemagne, Australie, France, Italie, États-Unis
- Bade-Wurtemberg, Californie, District de Karlsruhe, Michigan, Utah, Washington (État)
- Mannheim
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003A54
- to stream PubMed, to step Curation: 003925
- to stream PubMed, to step Checkpoint: 003925
- to stream Ncbi, to step Merge: 001523
- to stream Ncbi, to step Curation: 001523
- to stream Ncbi, to step Checkpoint: 001523
- to stream Main, to step Merge: 003856
- to stream Main, to step Curation: 003822
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.</title><author><name sortKey="Soverini, Simona" sort="Soverini, Simona" uniqKey="Soverini S" first="Simona" last="Soverini">Simona Soverini</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. Electronic address: simona.soverini@tin.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Branford, Susan" sort="Branford, Susan" uniqKey="Branford S" first="Susan" last="Branford">Susan Branford</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Pathology, SA Pathology, Centre for Cancer Biology, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Molecular Pathology, SA Pathology, Centre for Cancer Biology, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea><wicri:noRegion>Pierre Bénite</wicri:noRegion><wicri:noRegion>Pierre Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Talpaz, Moshe" sort="Talpaz, Moshe" uniqKey="Talpaz M" first="Moshe" last="Talpaz">Moshe Talpaz</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Deininger, Michael W N" sort="Deininger, Michael W N" uniqKey="Deininger M" first="Michael W N" last="Deininger">Michael W N. Deininger</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Muller, Martin C" sort="Muller, Martin C" uniqKey="Muller M" first="Martin C" last="Müller">Martin C. Müller</name><affiliation wicri:level="3"><nlm:affiliation>III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Radich, Jerald P" sort="Radich, Jerald P" uniqKey="Radich J" first="Jerald P" last="Radich">Jerald P. Radich</name><affiliation wicri:level="2"><nlm:affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, University of California, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, University of California, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24131888</idno><idno type="pmid">24131888</idno><idno type="doi">10.1016/j.leukres.2013.09.011</idno><idno type="wicri:Area/PubMed/Corpus">003A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A54</idno><idno type="wicri:Area/PubMed/Curation">003925</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003925</idno><idno type="wicri:Area/PubMed/Checkpoint">003925</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003925</idno><idno type="wicri:Area/Ncbi/Merge">001523</idno><idno type="wicri:Area/Ncbi/Curation">001523</idno><idno type="wicri:Area/Ncbi/Checkpoint">001523</idno><idno type="wicri:Area/Main/Merge">003856</idno><idno type="wicri:Area/Main/Curation">003822</idno><idno type="wicri:Area/Main/Exploration">003822</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.</title><author><name sortKey="Soverini, Simona" sort="Soverini, Simona" uniqKey="Soverini S" first="Simona" last="Soverini">Simona Soverini</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. Electronic address: simona.soverini@tin.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Branford, Susan" sort="Branford, Susan" uniqKey="Branford S" first="Susan" last="Branford">Susan Branford</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Pathology, SA Pathology, Centre for Cancer Biology, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Molecular Pathology, SA Pathology, Centre for Cancer Biology, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea><wicri:noRegion>Pierre Bénite</wicri:noRegion><wicri:noRegion>Pierre Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Talpaz, Moshe" sort="Talpaz, Moshe" uniqKey="Talpaz M" first="Moshe" last="Talpaz">Moshe Talpaz</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Deininger, Michael W N" sort="Deininger, Michael W N" uniqKey="Deininger M" first="Michael W N" last="Deininger">Michael W N. Deininger</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Muller, Martin C" sort="Muller, Martin C" uniqKey="Muller M" first="Martin C" last="Müller">Martin C. Müller</name><affiliation wicri:level="3"><nlm:affiliation>III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Radich, Jerald P" sort="Radich, Jerald P" uniqKey="Radich J" first="Jerald P" last="Radich">Jerald P. Radich</name><affiliation wicri:level="2"><nlm:affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, University of California, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, University of California, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Leukemia research</title><idno type="eISSN">1873-5835</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DNA Mutational Analysis (methods)</term><term>DNA Mutational Analysis (trends)</term><term>Drug Resistance, Neoplasm (genetics)</term><term>Forecasting</term><term>Fusion Proteins, bcr-abl (genetics)</term><term>Humans</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics)</term><term>Mutation</term><term>Practice Guidelines as Topic</term><term>Prognosis</term><term>Protein Kinase Inhibitors (pharmacology)</term><term>Protein Kinase Inhibitors (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de mutations d'ADN ()</term><term>Analyse de mutations d'ADN (tendances)</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Inhibiteurs de protéines kinases (pharmacologie)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Leucémie myéloïde chronique BCR-ABL positive (génétique)</term><term>Leucémie myéloïde chronique BCR-ABL positive (traitement médicamenteux)</term><term>Mutation</term><term>Pronostic</term><term>Protéines de fusion bcr-abl (génétique)</term><term>Prévision</term><term>Résistance aux médicaments antinéoplasiques (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Fusion Proteins, bcr-abl</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Neoplasm</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Leucémie myéloïde chronique BCR-ABL positive</term><term>Protéines de fusion bcr-abl</term><term>Résistance aux médicaments antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>DNA Mutational Analysis</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Analyse de mutations d'ADN</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie myéloïde chronique BCR-ABL positive</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>DNA Mutational Analysis</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Forecasting</term><term>Humans</term><term>Mutation</term><term>Practice Guidelines as Topic</term><term>Prognosis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de mutations d'ADN</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Mutation</term><term>Pronostic</term><term>Prévision</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Italie</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>Californie</li><li>District de Karlsruhe</li><li>Michigan</li><li>Utah</li><li>Washington (État)</li></region><settlement><li>Mannheim</li></settlement></list><tree><country name="Italie"><noRegion><name sortKey="Soverini, Simona" sort="Soverini, Simona" uniqKey="Soverini S" first="Simona" last="Soverini">Simona Soverini</name></noRegion><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name></country><country name="Australie"><noRegion><name sortKey="Branford, Susan" sort="Branford, Susan" uniqKey="Branford S" first="Susan" last="Branford">Susan Branford</name></noRegion></country><country name="France"><noRegion><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name></noRegion></country><country name="États-Unis"><region name="Michigan"><name sortKey="Talpaz, Moshe" sort="Talpaz, Moshe" uniqKey="Talpaz M" first="Moshe" last="Talpaz">Moshe Talpaz</name></region><name sortKey="Deininger, Michael W N" sort="Deininger, Michael W N" uniqKey="Deininger M" first="Michael W N" last="Deininger">Michael W N. Deininger</name><name sortKey="Radich, Jerald P" sort="Radich, Jerald P" uniqKey="Radich J" first="Jerald P" last="Radich">Jerald P. Radich</name><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Muller, Martin C" sort="Muller, Martin C" uniqKey="Muller M" first="Martin C" last="Müller">Martin C. Müller</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003822 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003822 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24131888
|texte= Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24131888" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |